BioCentury
ARTICLE | Clinical News

SUBA-Itraconazole: Interim Phase IIb data

August 8, 2016 7:00 AM UTC

Interim data from 13 patients with BCC nevus syndrome (Gorlin Syndrome) in the open-label, U.S. Phase IIb SCORING trial showed that twice-daily 150 mg oral SUBA-Itraconazole for >=16 weeks reduced tar...